Composition: Each film coated tablet contains Baricitinib INN 2.00 mg.

Indication: Baricitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. Limitation of Use: • Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressant’s such as azathioprine and cyclosporine. • For the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. • It is indicated for the treatment of adult patients with severe alopecia areata.

Dosage and administration: The recommended dose of Barictinib is 2 mg once daily. It may be used as monotherapy or in combination with methotrexate or other DMARDs. It is given orally with or without food. Lymphopenia: It should be avoided the initiation or interrupt in patients with an Absolute Lymphocyte Count less than 500 cells/mm3. Alopecia Areata: 2mg once daily. Increase to 4mg once daily, if the response to treatment is not adequate. Or, as directed by the registered physician.

Administration instruction: • Rheumatoid Arthritis and Alopecia Areata: Avoid initiation or interrupt Barinib in patients with anemia (hemoglobin<8 g/dL) or neutropenia (ANC <1000 cells/mm3).

• COVID-19: Avoid initiation or interrupt Barinib in patients with lymphopenia (ALC <200 cells/mm3) or neutropenia (ANC <500 cells/mm3).

Use in Pregnancy and lactation: Pregnancy: This medicine may cause fetal harm. Lactation: Advise not to breastfeed.

Packing: Each box contains 60's tablets in a blister pack.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.